The role of APRIL and BAFF in lymphocyte activation
- PMID: 15886118
- DOI: 10.1016/j.coi.2005.04.005
The role of APRIL and BAFF in lymphocyte activation
Abstract
The TNF family ligands BAFF (also called BLyS) and APRIL regulate lymphocyte survival and activation. BAFF binds to three receptors, BAFF-R, TACI and BCMA, whereas APRIL interacts with TACI, BCMA and proteoglycans. The contribution of BAFF and APRIL to B-cell and plasma-cell survival, CD154 (CD40L)-independent antibody isotype switching, germinal center maintenance, T-dependent and T-independent antibody responses, and T cell co-stimulation are relatively well understood. Constitutive BAFF produced by stromal cells determines the size of the peripheral B cell pool, whereas inducible BAFF produced by myeloid and other cells supports local survival of B lymphocytes and can be associated with development of autoimmunity when deregulated.
Similar articles
-
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.Biochemistry. 2005 Feb 15;44(6):1919-31. doi: 10.1021/bi048227k. Biochemistry. 2005. PMID: 15697217
-
Identification of proteoglycans as the APRIL-specific binding partners.J Exp Med. 2005 May 2;201(9):1375-83. doi: 10.1084/jem.20042309. Epub 2005 Apr 25. J Exp Med. 2005. PMID: 15851487 Free PMC article.
-
TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties.Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):263-76. doi: 10.1016/j.cytogfr.2008.04.006. Epub 2008 Jun 2. Cytokine Growth Factor Rev. 2008. PMID: 18514565 Review.
-
Novel function of TNF cytokines in regulating bone marrow B cell survival.Cell Mol Immunol. 2004 Dec;1(6):447-53. Cell Mol Immunol. 2004. PMID: 16293214
-
BAFF, APRIL and their receptors: structure, function and signaling.Semin Immunol. 2006 Oct;18(5):263-75. doi: 10.1016/j.smim.2006.04.006. Epub 2006 Aug 17. Semin Immunol. 2006. PMID: 16914324 Review.
Cited by
-
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.PLoS One. 2016 Aug 18;11(8):e0161226. doi: 10.1371/journal.pone.0161226. eCollection 2016. PLoS One. 2016. PMID: 27536947 Free PMC article. Clinical Trial.
-
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss.Cancer Cell Int. 2021 Apr 17;21(1):223. doi: 10.1186/s12935-021-01923-x. Cancer Cell Int. 2021. PMID: 33865370 Free PMC article.
-
Inhibiting B cell activating factor attenuates preeclamptic symptoms in placental ischemic rats.Am J Reprod Immunol. 2023 Apr;89(4):e13693. doi: 10.1111/aji.13693. Epub 2023 Feb 27. Am J Reprod Immunol. 2023. PMID: 36794639 Free PMC article.
-
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.Antibodies (Basel). 2017 Nov 14;6(4):18. doi: 10.3390/antib6040018. Antibodies (Basel). 2017. PMID: 31548533 Free PMC article. Review.
-
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.Arthritis Res Ther. 2006;8(6):R167. doi: 10.1186/ar2076. Arthritis Res Ther. 2006. PMID: 17092341 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous